Date published: 2025-10-10

00800 4573 8000

SCBT Portrait Logo
Seach Input

MerTK Inibidores

MerTK inhibitors represent a specialized category of chemical compounds designed to specifically target and impede the activity of the MerTK receptor tyrosine kinase. MerTK, an abbreviation for Mer Tyrosine Kinase, is a prominent member of the TAM (Tyro3, Axl, and Mer) family of receptor kinases, which exert pivotal control over numerous cellular processes. Predominantly expressed on the surfaces of phagocytic cells, such as macrophages and dendritic cells, MerTK activation plays a central role in recognizing and engulfing apoptotic cells and cellular debris, a fundamental aspect of the body's immune response and tissue equilibrium. However, when MerTK becomes dysregulated or experiences overexpression, it has been linked to various diseases, including cancer, autoimmune disorders, and chronic inflammation.

Consequently, MerTK inhibitors have been meticulously engineered to selectively disrupt MerTK's signaling pathways. These inhibitors primarily function by binding to the catalytic site of MerTK, effectively obstructing the receptor's ability to phosphorylate downstream signaling molecules. Consequently, they interrupt its cellular functions, exerting influence over vital processes such as phagocytosis, cytokine production, and interactions between immune cells. The ramifications of MerTK inhibition extend to diseases characterized by irregular cell clearance, immune evasion, or tissue remodeling. Researchers are continually refining MerTK inhibitors, exploring their capacity to address health challenges associated with MerTK-related cellular pathways.

VEJA TAMBÉM

Items 1 to 10 of 13 total

Mostrar:

Nome do ProdutoCAS #Numero de CatalogoQuantidadePrecoUso e aplicacaoNOTAS

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Inibe as tirosina-quinases, em particular a BCR-ABL e a c-KIT, bloqueando as vias de sinalização celular nas células cancerígenas.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Tem como alvo as cinases RAF e VEGFR, impedindo a proliferação celular e a angiogénese no cancro.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Inibe o recetor do fator de crescimento epidérmico (EGFR), impedindo o crescimento e a divisão celular no cancro do pulmão.

MDV3100

915087-33-1sc-364354
sc-364354A
5 mg
50 mg
$240.00
$1030.00
7
(1)

Bloqueia o recetor de androgénio, impedindo a sua ativação nas células cancerígenas da próstata.

BMS 777607

1025720-94-8sc-364438
sc-364438A
10 mg
50 mg
$392.00
$1244.00
1
(1)

O BMS-777607 é um inibidor da tirosina quinase multiobjectivo. O seu mecanismo envolve a ligação aos locais de ligação ATP das cinases MET, AXL, Ron e Tyro3, entre as quais a MerTK é inibida. A sua natureza multi-alvo sugere que pode ser bloqueada uma gama mais vasta de vias oncogénicas.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

Inibe o mTOR, reduzindo o crescimento celular e a angiogénese em vários tipos de cancro.

Erlotinib, Free Base

183321-74-6sc-396113
sc-396113A
sc-396113B
sc-396113C
sc-396113D
500 mg
1 g
5 g
10 g
100 g
$85.00
$132.00
$287.00
$495.00
$3752.00
42
(0)

Tem como alvo o EGFR, impedindo o crescimento celular no cancro do pulmão de células não pequenas.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

Inibe JAK1 e JAK2, modulando a sinalização de citocinas em neoplasias mieloproliferativas.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Bloqueia múltiplas tirosina-quinases, incluindo BCR-ABL, inibindo o crescimento na leucemia mieloide crónica.

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

Tem como alvo tanto o EGFR como o HER2, interrompendo as vias de sinalização nas células do cancro da mama.